Evidence map›Paper›PMID 31413201›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Sumit K Matta, Philipp Olias, Zhou Huang, Qiuling Wang, Eugene Park, Wayne M Yokoyama, L David Sibley

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Dense granule proteins: key mediators ofFrontiers in medicine · 2026
    Review
  6. Article
  7. Article
  8. Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  9. Article
  10. Article
  11. Interferons andFrontiers in immunology · 2025
    Article
  12. Review
  13. International journal of molecular sciences · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Mutual regulations betweenFrontiers in immunology · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sumit K MattaDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.
Philipp OliasDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.
Zhou HuangDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.
Qiuling WangDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.
Eugene ParkDepartment of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.ORCID 0000-0002-2617-7571
Wayne M YokoyamaDepartment of Internal Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63130.
L David SibleyDepartment of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63130; sibley@wustl.edu.
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
Molecular Basis of Human ToxoplasmosisR01AI118426 · NIAID · WASHINGTON UNIVERSITY · PI SIBLEY, L. DAVID · 2015 to 2024
$6.0M
INHIBITION OF STAT TRANSCRIPTION BY TOXOPLASMAR21AI119744 · NIAID · WASHINGTON UNIVERSITY · PI SIBLEY, L. DAVID · 2017 to 2018
$419k
NCI NIH HHS P30 CA091842NIAID NIH HHS R01 AI118426NIAID NIH HHS R21 AI119744
6 · The paper itself

Abstract

In contrast to the importance of type II interferon-γ (IFN-γ) in control of toxoplasmosis, the role of type I IFN is less clear. We demonstrate here that TgIST, a secreted effector previously implicated in blocking type II IFN-γ signaling, also blocked IFN-β responses by inhibiting STAT1/STAT2-mediated transcription in infected cells. Consistent with a role for type I IFN in cell intrinsic control, ∆

Indexed as

Signal TransductionGene Expression ProfilingHumansInterferon Type IKiller Cells, NaturalMi-2 Nucleosome Remodeling and Deacetylase ComplexMonocytesProtein BindingProtein MultimerizationProtozoan ProteinsSTAT1 Transcription FactorSTAT2 Transcription FactorToxoplasmaToxoplasmosisInterferon Type IMi-2 Nucleosome Remodeling and Deacetylase ComplexProtozoan ProteinsSTAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription Factorcentral nervous systeminflammatory monocyteinterferonNK celltranscriptome

Identifiers

PMID31413201
PMCPMC6717281
OpenAlexW2969148180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.